Place de l’immunothérapie dans le traitement des carcinomes épidermoïdes de la tête et du cou.
23 июня 2021 года
20:30
Place de l’immunothérapie dans le traitement des carcinomes épidermoïdes de la tête et du cou.
Текст новости:
Title: Place de l’immunothérapie dans le traitement des carcinomes épidermoïdes de la tête et du cou.
Author, co-author: Lecocq, Marie; Poncin, Aurélie; Sautois, Brieuc
Abstract: Current recommendations for systemic treatments of head and neck squamous cell carcinoma have been significantly modified with the advent of immunotherapy for a majority of these cancers. Indeed, immune checkpoint inhibitors are now recommended in metastatic disease and in locoregional recurrence not amenable to a local treatment. PD-L1 positive tumours are eligible for immunotherapy in first line and immunotherapy is also available in second line, after failure of platinum based chemotherapy, regardless of PD-L1 expression. Ongoing clinical trials are exploring the role of immune checkpoint inhibitors in the adjuvant setting as well as with radiotherapy as definitive treatment. Immunotherapy has changed the treatment landscape and has improved the prognosis of patients with head and neck squamous cell carcinoma.


Текст со страницы (автоматическое получение):
Place de l’immunothérapie dans le traitement des carcinomes épidermoïdes de la tête et du cou.
Author, co-author :
Publication date :
Keywords :
[en] Head and Neck Neoplasms/therapy ; Humans ; Immunotherapy ; Neoplasm Recurrence, Local ; Prognosis ; Squamous Cell Carcinoma of Head and Neck/therapy ; Chemotherapy ; Immunotherapy ; Squamous cell carcinoma ; Head and neck cancer
Abstract :
[en] Current recommendations for systemic treatments of head and neck squamous cell carcinoma have been significantly modified with the advent of immunotherapy for a majority of these cancers. Indeed, immune checkpoint inhibitors are now recommended in metastatic disease and in locoregional recurrence not amenable to a local treatment. PD-L1 positive tumours are eligible for immunotherapy in first line and immunotherapy is also available in second line, after failure of platinum based chemotherapy, regardless of PD-L1 expression. Ongoing clinical trials are exploring the role of immune checkpoint inhibitors in the adjuvant setting as well as with radiotherapy as definitive treatment. Immunotherapy has changed the treatment landscape and has improved the prognosis of patients with head and neck squamous cell carcinoma.
Permalink :
Автоматическая система мониторинга и отбора информации
Источник
Другие материалы рубрики
★★★  23 июня 2021 года
15:43
Carbon capture and re use: technological and other challenges